The insider sales are small relative to market cap and likely reflect routine post-IPO diversification by pre-revenue biotech executives. No bearish read-through — monitor next pipeline catalyst (likely Phase 2 data readout) for fundamental direction.
Price Chart
Executive Summary
Two top insiders at Rapport Therapeutics (CEO and Chief Development Officer) sold a combined ~$1.98M in open-market sales over two days (Aug 24–25), with the CEO alone selling $938K. The cluster represents ~0.08% of the $2.5B market cap, falling below the 0.1% materiality threshold. The sales are likely routine post-IPO/vesting-related liquidity events, not a bearish signal, especially given the strong analyst consensus (95% bullish) and the company's pre-revenue biotech status where insider sales are common for diversification.
Key Financial Metrics
Key Facts
- CEO Ceesay Abraham sold 18,921 shares at $49.57 for $938K on Aug 25
- Chief Development Officer Krishnaswamy Yeleswaram sold 50,160 shares total (~$2.53M) across Aug 24–25
- Total cluster value of ~$1.98M represents ~0.08% of $2.5B market cap
- Both sales were open-market (code S) — no 10b5-1 plan indicated in filing
- Analyst consensus is 95% bullish (18 Buy/8 Strong Buy, 1 Hold) with no Sell ratings
Financial Impact
Insider sales of ~$1.98M, or 0.08% of market cap — immaterial relative to company size
Risk Factors
- CEO selling near $50 could signal peak valuation sentiment if followed by more C-suite sales
- Pre-revenue biotech carries binary pipeline risk regardless of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RAPP-1787810982173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers